Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, developing protein therapeutics that target dysfunctional signaling within the TGF-β family — pathways that regulate muscle, bone, fat, heart tissue and blood. Its most advanced asset, elritercept, is licensed to Takeda for development in cytopenias associated with myelodysplastic syndromes and myelofibrosis, while its lead wholly owned candidate, rinvatercept, is aimed at Duchenne muscular dystrophy and ALS.
Shares traded at $10.69 in Tuesday's session, a gain of 6.58% from the prior close of $10.03. The direction was firmly positive, with the move following a pair of verified disclosures: a new share repurchase authorization announced after Monday's close and an analyst price-target revision published Monday morning.
The clearest catalyst arrived late Monday, when the company said its board approved a new program to repurchase up to $5 million of common stock. The authorization followed receipt of a $20 million development milestone under the elritercept license with Takeda Pharmaceuticals U.S.A., triggered by dosing of the first patient in the ELRiSE MF clinical trial in myelofibrosis.
Two things about the disclosure matter to investors. First, the $20 million milestone is fresh cash equal to roughly a tenth of the company's market value. Second, management is directing part of it toward shareholders rather than spending it all on development. Keros reported $259.5 million of cash and equivalents at September 30 and now projects that, after the milestone and the repurchase, funding will carry operations and capital spending into 2029 — an extension from the second half of 2028 previously guided. Importantly, the program carries no obligation to buy a specific number of shares and can be suspended at any time, which tempers the signal.
BofA Securities raised its price target on Keros to $18 from $17 and reiterated a Neutral rating, updating its model after the third-quarter report. The revision is supportive but incremental — it lifts the implied upside without changing the firm's stance, and it followed a quarter that produced a spectacular headline beat.
The move is also a recovery trade. On November 5 the company reported third-quarter revenue of $40.0 million and GAAP earnings of $0.70 per share, both far above consensus, yet the stock plunged 12.7% the next session as investors focused on the non-recurring nature of license revenue and the absence of product sales. Selling continued to $8.98 on November 10, a 52-week low and the floor of the 52-week range of $8.97 to $22.41. Buyers have stepped in since, lifting shares 19% off that low even before Tuesday's advance.
Early-session turnover looked light relative to the stock's three-month average daily volume of roughly 187,000 shares, suggesting the gain reflected a thinning order book rather than a large institutional accumulation. The stock is a micro-cap with a market value near $200 million and close to 1.1 million shares sold short, about 5.5% of the float — enough for short covering to amplify headline-driven moves.
Technically, the advance is repairing damage but has not reversed the trend. Keros remains below its 50-session average of approximately $11.02 and well below the $11.95 October peak. A close above $11 would mark the first meaningful higher close in a month; a failure there keeps the September-to-November downtrend intact. The gap left by the November 6 selloff around $10.83 is the nearest overhead obstacle.
The score runs from 0 to 100, where 0 means no meaningful news and a normal move, and 100 means transformative news and an extreme, rare price move. Keros earns 38 out of 100.
The verified news was moderate rather than major: $25 million of combined cash inflow and buyback capacity is material for a company of this size, but the repurchase is discretionary and no clinical data changed hands. The price move was roughly three times the stock's typical daily absolute change of about 2.2%, and a move this large occurred only twice in the past 60 sessions. Modest news and a moderately unusual move combine into a below-midpoint score.
The next hard catalyst is initial Phase 2 data for rinvatercept in Duchenne muscular dystrophy, guided for the first half of 2027, alongside regulatory discussions on a planned ALS study. Fourth-quarter and full-year 2026 results are expected in early 2027, in line with the company's recent reporting cadence, and seven covering analysts hold a consensus Buy rating with an average target near $20.
Risks cut both ways. Elritercept economics now sit largely with Takeda, so Keros depends on milestones and royalties rather than product revenue, and license income will be lumpy and non-repeating. Clinical timelines in neuromuscular disease slip frequently, and the company still burns cash. Watch whether management actually executes buybacks, since unexercised authorizations have limited effect on the share count.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market conditions change. Reviewing the current leaders is a practical way to see which approaches are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
On November 13, 2026, the Stochastic Oscillator for KROS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 49 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Indicator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +7.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In 68 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 33 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
KROS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.586). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology